Innovative Gas Sensors Expand SSB's PAT Portfolio
Sartorius Stedim Biotech (SSB), a leading international supplier of pharmaceutical and biotech equipment, has entered into a global sales partnership with BlueSens, the German experts in gasometric engineering. BlueSens is a highly specialized provider of sensor technology, which is used by the biopharmaceutical industry for inline measurement of gases in microbial fermentation and cell cultivation processes. The co-operation agreement between SSB and BlueSens provides that, alongside BlueSens, SSB will assume global marketing and distribution of its partner company’s oxygen and carbon dioxide sensors, and sell these as private label products under SSB’s brand name BioPAT Xgas.
During the past years, SSB has continuously expanded its process analytics portfolio in the area of sensor technology to measure critical process parameters, such as pH and dissolved oxygen, temperature, glucose, lactate and biomass, non-invasively and in real time. The new oxygen and carbon dioxide sensors are further important additions to SSB’s range of analytical products. BioPAT Xgas enables precise, reproducible information to be obtained about the progress of fermentation, without having to take samples and analyze them off-line in a laboratory.
Stefan Schlack, Senior Vice President of Marketing at SSB, said: "These sensors make our bioreactors even more intelligent. They analyse metabolic processes in real time during cultivation and help our customers better understand their processes. Used in combination with our software, these sensors are powerful tools for optimizing biopharmaceutical production processes and accelerating development."
Dr Holger Müller, Sales and Marketing Manager at BlueSens, stated: “In fermentation, SSB is among the leading suppliers worldwide and has a strong, global sales network. We would like to leverage these advantages to reach considerably more customers. I am looking forward to our partnership.“
BioPAT Xgas will be sold as an equipment package that includes SSB’s single-use and reusable bioreactors. Ready to use right out of the box, the sensors are completely integrated into SSB’s BioPAT DCU control units and SCADA software, called BioPAT MFCS.
In conjunction with Sartorius software, BioPAT Xgas analyses critical process variables, such as oxygen uptake rate (OUR), carbon dioxide production rate (CPR) or respiratory quotient (RQ).
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance